
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
about 28 years ago
Participating Facultyabout 28 years ago
Selected Abstractsabout 28 years ago
Bibliography





